<DOC>
	<DOCNO>NCT00004903</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy peripheral stem cell transplantation treat patient multiple myeloma .</brief_summary>
	<brief_title>Combination Chemotherapy Peripheral Stem Cell Transplantation Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine feasibility activity intensive therapy 3 noncross resistant chemotherapeutic regimen ( cyclophosphamide , etoposide , cisplatin , cytarabine , tandem course high dose melphalan stem cell rescue ) patient chemotherapy sensitive multiple myeloma . II . Determine incidence hematologic nonhematologic toxicity regimen patient population . III . Determine time hematologic recovery high dose melphalan patient . IV . Determine response rate course therapy patient . V. Determine disease free , relapse free , overall survival patient treat regimen . VI . Determine incidence toxicity attributable interferon alfa ability continue interferon alfa therapy maintenance patient . OUTLINE : Patients stratify accord number prior treatment ( 1 vs 2 ) . Patients receive cyclophosphamide IV 1 hour every 3 hour 5 dos . Filgrastim ( G-CSF ) administer subcutaneously daily begin 3 day cyclophosphamide continue apheresis . Upon hematologic recovery , peripheral blood stem cell ( PBSC ) collect several day . After completion autologous stem cell harvest hematologic recovery , patient receive etoposide IV cisplatin IV continuously 4 day , follow cytarabine IV 2 hour . Beginning 4-6 week later , patient receive melphalan IV 15 minute 2 consecutive day . At least 48 hour second dose melphalan , PBSC reinfused . G-CSF administer subcutaneously daily begin 5 day PBSC reinfusion hematologic recovery . Patients remain remission first course high dose melphalan receive second course melphalan 4 6 month first course . Melphalan IV administer reinfusion remainder PBSC . After hematologic recovery second transplant , patient receive interferon alfa subcutaneously 3 day weekly relapse . Patients follow every 2 month . PROJECTED ACCRUAL : Approximately 28 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : All stage multiple myeloma Measurable disease manifest monoclonal serum urine globulin If nonsecretory , must malignant plasma cell document bilateral bone marrow biopsy isolate plasmacytomas Complete remission induction chemotherapy allow No progressive disease standard induction therapy PATIENT CHARACTERISTICS : Age : Physiologic 65 Performance status : CALGB 01 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL No active hepatitis hepatitis C Renal : Creatinine le 2.0 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : LVEF least 45 % No history symptomatic coronary artery disease unless clear cardiology evaluation Pulmonary : FEV1 least 60 % predict FEV1/FVC least 60 % Other : HIV negative Hepatitis B surface antigen negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No 2 prior chemotherapy regimen , include induction Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2001</verification_date>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>